Steven Lane
Professor | Group Leader
Gordon & Jessie Gilmour Leukaemia Research Laboratory
+61 7 3362 0222steven.lane@qimrberghofer.edu.au
CAREER HISTORY
Professor Steven Lane is a clinical haematologist and devotes 30% of his time to seeing patients with leukaemia and related blood disorders at the Royal Brisbane and Women’s Hospital. Professor Lane is active in clinical trials including as principal investigator on prospective clinical trials in acute leukaemia and has accredited GCP training.
CURRENT APPOINTMENTS
- Group Leader, Gordon and Jessie Gilmour Leukaemia Research Laboratory
- Consultant Haematologist, Royal Brisbane and Women’s Hospital (RBWH)
- Director of Clinical Research, Cancer Care Services, RBWH
- Professor, University of Queensland
- Adjunct Associate Professor, Queensland University of Technology
- Head, Cancer Theme, Brisbane Diamantina Health Partners
- Member of National Blood Cancer Forum
PREVIOUS APPOINTMENTS
2011-2016: Team Head, Gordon and Jessie Gilmour Leukaemia Research Laboratory, QIMR Berghofer
2012-2014: Senior Lecturer, University of Queensland
2010-2011: Instructor in Paediatrics, Harvard Medical School, Children’s Hospital Boston
2008-2010: Postdoctoral Research Fellow, Harvard Medical School USA
2003-2008: Associate Lecturer, University of Queensland Medical School
2003-2008: Haematology Registrar, Queensland Health – RBWH and Princess Alexandra Hospital
1999-2001: Resident Medical Officer, Queensland Health – RBWH
ORCID NUMBER
RESEARCHER ID
CURRENT AREA OF RESEARCH
- the laboratory researches myeloid blood cancers such as acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and the myeloproliferative neoplasms (MPN). These are very aggressive and rapidly fatal blood cancers that are among the most common types of cancer affecting Australians. Our efforts are concentrated on understanding how leukaemia stem cells in AML and MPN are able to regenerate leukaemia (or cause relapse in patients), even after cytotoxic chemotherapy. To achieve this, research has focused on generating robust models of leukaemia and dissecting the pathways of self-renewal in leukaemia stem cells and normal blood stem cells
- Myeloproliferative neoplasms (MPN) – targeting disease-initiating stem cell populations through targeted inhibitors of Jak2 signaling or through inhibition of self-renewal pathways within stem cell populations
- Acute myeloid leukaemia (AML) – examining the effect of inhibitors used alone, or in combination with chemotherapy on the preferential dependency of AML stem cells (compared to normal bone marrow) on pathways regulating DNA damage response and chromosomal stability. Identifying novel LSC-specific targets that may be of broader interest
- normal blood development and pathways that regulate blood stem cell development
RESEARCH HIGHLIGHTS
- targeting stem cells in myeloproliferative neoplasm
- in vivo transformation of normal stem cells with Cdx2 leads to the development of MDS and AML
- molecular screening and therapy in Leukaemia and Lymphoma (MoSTLLY) a translational clinical trials program to identify effective therapies for patients with blood cancer
PROFESSIONAL MEMBERSHIPS
2019
- Treasurer & Queensland Councillor, Haematology Society of Australia and New Zealand
2013
- European Hematology Association
2011
- Australasian Leukaemia and Lymphoma Group
2010
- AHPRA (formerly Queensland Medical Board)
- International Society of Experimental Hematology
2008
- American Society of Hematology
2005
- Haematology Society of Australia and New Zealand
- Royal College of Pathologists of Australasia
2001
- Royal Australasian College of Physician
1999-2010
- Queensland Medical Board (now AHPRA)
Life Member: Fulbright Alumni Association
AWARDS RECOGNITION
2019
- Ralph Doherty QIMR Berghofer Prize for outstanding achievement and leadership in Medical research
2018
- Metro North Research Awards: Discovery and Innovation – Highly Commended
2017-2021
- CSL Centenary Fellowship ($1,250,000)
2017-2019
- Associate Member of the Australian Academy of Health and Medical Sciences
2017
- Cure Cancer Australia: Researcher of the Year
2016
- nominated, NHMRC Gottshalke Award
- finalist, Queensland Health Metro North Research Excellence Awards
- nominated, Metcalf Award, Australian Society for Stem Cell Research
2015
- finalist, BUPA Emerging Researcher Award
- Mercator Fellow, Otto Von-Guerike University Hospital, Magdeburg Germany
2014-2016
- National Health and Medical Research Council (NHMRC) Career Development Fellowship
2013
- University of Queensland Dean’s Award for Research Higher Degree Excellence
2011-2014
- Leukaemia Foundation of Australia/Cure Cancer Foundation Postdoctoral Fellowship
2008
- NHMRC Postgraduate Award
2007
- Fulbright Postgraduate Scholarship, Alumni (WG Walker) Award for top ranked postgraduate scholarship
- Haematology Society of Australia and New Zealand/ Novartis, Young Investigator Award
- Royal College of Pathologists of Australasia Travel Grant
2006
- Haematology Society of Australia and New Zealand, Queensland Branch Travel Award
- Royal Australasian College of Physicians Advanced Trainee Research Award Queensland
1999
- AMAQ memorial prize University of Queensland, Awarded for the top student in clinical medicine
EDUCATIONAL BACKGROUND
2012: PhD, University of Queensland School of Medicine
2008: Fellow Royal Australasian College of Physicians (Clinical Haematology)
2008: Fellow Royal College of Pathologists of Australasia (Haematopathology)
1999: Bachelor of Medicine, Bachelor of Surgery, Honours (Class II), University of Queensland